.Nature Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after an average follow-up of 11 months, clients with metastatic gastrointestinal growths who obtained biomarker-matched treatments based upon spreading cyst DNA profiling revealed a more significant medical advantage than those obtaining incomparable therapy.